文献速递糖尿病

新型双激素胰岛素与普兰林肽人工胰腺治疗1型糖尿病:随机对照交叉试验

A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial.
PubMed 文献 · Diabetes Care · 2020-01-23

该随机交叉试验在1型糖尿病成人中比较快速胰岛素单用人工胰腺与快速胰岛素联合普兰林肽及常规胰岛素联合普兰林肽双激素人工胰腺。主要结局为血糖在3.9-10.0 mmol/L范围内的时间比例。快速胰岛素联合普兰林肽系统较快速胰岛素单用系统提高达标时间(74%对84%,P=0.0014),常规胰岛素联合普兰林肽系统无变化(69%,P=0.22)。

要点

  • 快速胰岛素联合普兰林肽双激素人工胰腺较快速胰岛素单用系统提高血糖达标时间(74%对84%,P=0.0014)。
  • 达标时间提高源于日间控制改善(日间达标时间从63%升至78%,P=0.0004)。
  • 快速胰岛素联合普兰林肽系统胃肠道症状发生率6%(6/108餐),常规胰岛素联合普兰林肽系统11%(11/104餐),均无严重症状。

核心结论

  • 新型快速胰岛素联合普兰林肽人工胰腺较快速胰岛素单用人工胰腺改善血糖控制(ClinicalTrials.gov注册号NCT02814123)。

研究设计与样本

  • 随机交叉试验,在1型糖尿病成人中比较快速胰岛素单用人工胰腺与快速胰岛素联合普兰林肽及常规胰岛素联合普兰林肽双激素人工胰腺系统。
  • 受试者按随机顺序在三次24小时住院访视中接受干预,每次访视前有10-14天门诊激素开环导入期。
  • 双激素人工胰腺以基础-餐时方式输注普兰林肽,采用新型剂量算法,与胰岛素呈固定比例。
  • 主要结局为血糖在3.9-10.0 mmol/L范围内的时间比例。

主要发现

  • 快速胰岛素联合普兰林肽系统较快速胰岛素单用系统提高达标时间,从74%(标准差18%)升至84%(13%),P=0.0014。
  • 常规胰岛素联合普兰林肽系统未改变达标时间(69%[19%],P=0.22)。
  • 快速胰岛素联合普兰林肽系统达标时间提高源于日间控制改善,日间达标时间从63%(23%)升至78%(16%),P=0.0004。
  • 低血糖事件(<3.3 mmol/L伴症状或<3.0 mmol/L无论症状)在快速胰岛素单用系统为11次(每2.5天1次),快速胰岛素联合普兰林肽系统为12次(每2.3天1次),常规胰岛素联合普兰林肽系统为18次(每1.4天1次)。
  • 胃肠道症状在快速胰岛素单用系统餐后报告率为0%(0/112餐),快速胰岛素联合普兰林肽系统为6%(6/108餐),常规胰岛素联合普兰林肽系统为11%(11/104餐),均无严重症状。

关键数值与推荐

  • 主要结局达标时间:快速胰岛素单用系统74%(标准差18%),快速胰岛素联合普兰林肽系统84%(13%),常规胰岛素联合普兰林肽系统69%(19%)。
  • 日间达标时间:快速胰岛素单用系统63%(23%),快速胰岛素联合普兰林肽系统78%(16%),P=0.0004。
  • 低血糖事件(<3.3 mmol/L伴症状或<3.0 mmol/L无论症状):快速胰岛素单用系统11次(每2.5天1次),快速胰岛素联合普兰林肽系统12次(每2.3天1次),常规胰岛素联合普兰林肽系统18次(每1.4天1次)。
  • 胃肠道症状餐后报告率:快速胰岛素单用系统0%(0/112),快速胰岛素联合普兰林肽系统6%(6/108),常规胰岛素联合普兰林肽系统11%(11/104)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The rapid insulin-alone artificial pancreas improves glycemia in type 1 diabetes but daytime control remains suboptimal. We propose two novel dual-hormone artificial pancreas systems. RESEARCH DESIGN AND METHODS: We conducted a randomized crossover trial comparing a rapid insulin-alone artificial pancreas with rapid insulin-and-pramlintide and with regular insulin-and-pramlintide artificial pancreas systems in adults with type 1 diabetes. Participants were assigned to the interventions in random order during three 24-h inpatient visits. Each visit was preceded by an outpatient hormonal open-loop run-in period of 10-14 days. The dual-hormone artificial pancreas delivered pramlintide in a basal-bolus manner, using a novel dosing algorithm, with a fixed ratio relative to insulin. The primary outcome was time in the range 3.9-10.0 mmol/L. RESULTS: Compared with the rapid insulin-alone artificial pancreas system, the rapid insulin-and-pramlintide system increased the time in range from 74% (SD 18%) to 84% (13%) (P = 0.0014), whereas the regular insulin-and-pramlintide system did not change the time in range (69% [19%]; P = 0.22). The increased time in range with the rapid insulin-and-pramlintide system was due to improved daytime control (daytime time in range increased from 63% [23%] to 78% [16%], P = 0.0004). There were 11 (1 per 2.5 days) hypoglycemic events (<3.3 mmol/L with symptoms or <3.0 mmol/L irrespective of symptoms) with the rapid insulin-alone system, compared with 12 (1 per 2.3 days) and 18 (1 per 1.4 days) with the rapid and regular insulin-and-pramlintide systems, respectively. Gastrointestinal symptoms were reported after 0% (0 of 112) of meals with the rapid insulin-alone system, compared with 6% (6 of 108) and 11% (11 of 104) with the rapid and regular insulin-and-pramlintide systems, respectively; none of the symptoms were severe. CONCLUSIONS: A novel rapid insulin-and-pramlintide artificial pancreas improves glucose control compared with a rapid insulin-alone artificial pancreas (ClinicalTrials.gov number NCT02814123).

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Haidar A, Tsoukas MA, Bernier-Twardy S, et al. A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial. Diabetes Care. 2020. PMID: 31974099. doi:10.2337/dc19-1922

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。